FDA grants EUA for PathogenDx COVID-19 test

2021 04 27 22 24 2298 Nasal Swab Test 400

The U.S. Food and Drug Administration (FDA) has granted an emergency use authorization (EUA) to PathogenDx for the company's microarray-based COVID-19 test, DetectX-Rv.

DetectX-Rv is a reverse transcription polymerase chain reaction (RT-PCR) and DNA microarray test that uses material from nasopharyngeal, oropharyngeal, midturbinate, and anterior nasal swabs, as well as nasal aspirates, nasopharyngeal wash/aspirates, and bronchoalveolar lavage specimens from patients with suspected COVID-19, according to the firm.

Page 1 of 6
Next Page